Endpoints News 生物医药· Ayisha Sharma·· 24 天前AI 评分35
计提 19 亿美元减值后,Novartis 仍坚持 120 亿美元收购 Avidity Biosciences
After $1.9B impairment hit, Novartis stands by $12B bet on Avidity
AI 导读
Novartis CEO Vas Narasimhan 表示,对 Avidity Biosciences 的 120 亿美元收购“完全在轨”。此前 Novartis 披露 19 亿美元减值,Narasimhan 仍坚持这笔交易。
正文
Novartis’ $12 billion acquisition of Avidity Biosciences “remains absolutely on track,” CEO Vas Narasimhan said, after the company disclosed a $1.9 billion …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news